Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE N/A. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $170598 | $2M | $7M | $1M | $3M | $11M | $3M | — | — | — | — |
| Enterprise Value | $43M | $45M | $36M | $32M | $32M | $23M | $11M | — | — | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.01 | 0.19 | 0.64 | 0.12 | 0.24 | 2.54 | 0.32 | — | — | — | — |
| P/B Ratio | — | — | 1.15 | 0.24 | — | 1.00 | 1.00 | — | — | — | — |
| P/FCF | 0.03 | 0.38 | — | — | — | — | — | — | — | — | — |
| P/OCF | 0.03 | 0.37 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.89 | 3.08 | 3.26 | 2.69 | 5.38 | 1.18 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 7.76 | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.2% | 67.2% | 83.3% | 79.1% | 83.1% | 46.2% | 65.1% | 33.9% | 37.4% | 79.8% | 63.3% |
| Operating Margin | -398.8% | -398.8% | -263.8% | -351.3% | -287.8% | -939.1% | -283.9% | -501.3% | -698.0% | -785.3% | -9599.8% |
| Net Profit Margin | -465.4% | -465.4% | -329.3% | -423.1% | -396.9% | -1213.3% | -360.2% | -667.3% | -727.9% | -503.7% | -10410.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -675.8% | -2332.7% | -904.1% | -362.0% | -242.6% | -480.1% | -283.9% | -296.7% | -1515.1% |
| ROA | -116.8% | -116.8% | -73.9% | -84.1% | -94.2% | -109.4% | -85.3% | -99.5% | -75.9% | -93.1% | -184.5% |
| ROIC | -116.8% | -116.8% | -65.6% | -81.0% | -98.9% | -123.4% | -99.8% | -129.1% | -88.8% | -152.8% | -649.7% |
| ROCE | -292.5% | -292.5% | -87.5% | -127.3% | -125.4% | -120.8% | -105.2% | -163.5% | -144.6% | -248.0% | -345.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 5.62 | 7.57 | — | 2.48 | 0.94 | 0.71 | 2.99 | 0.95 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | 4.39 | 6.25 | — | 1.04 | 0.47 | 0.38 | 2.51 | 0.92 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 7.39 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -565.60 | -565.60 | -168.92 | -5.31 | -2.80 | -5.25 | -11.11 | -5.72 | -11.23 | -12.50 | -13.79 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.50 | 0.50 | 1.63 | 2.00 | 0.74 | 1.84 | 1.35 | 0.62 | 0.31 | 0.25 | 0.61 |
| Quick Ratio | 0.29 | 0.29 | 1.11 | 1.34 | 0.50 | 1.52 | 1.14 | 0.48 | 0.18 | 0.11 | 0.51 |
| Cash Ratio | 0.02 | 0.02 | 0.41 | 0.46 | 0.18 | 1.10 | 0.61 | 0.23 | 0.10 | 0.03 | 0.23 |
| Asset Turnover | — | 0.30 | 0.22 | 0.19 | 0.25 | 0.08 | 0.22 | 0.16 | 0.11 | 0.10 | 0.04 |
| Inventory Turnover | 0.44 | 0.44 | 0.19 | 0.22 | 0.29 | 0.48 | 1.18 | 1.79 | 0.83 | 0.42 | 0.13 |
| Days Sales Outstanding | — | 53.84 | 51.43 | 81.67 | 75.31 | 180.52 | 177.35 | 107.07 | 82.80 | 39.26 | 785.62 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 100.0% | 265.8% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 100.0% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 100.0% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $66640 | $8415 | $439 | $25 | $11 | $3 | $0 | $0 | $0 | $0 |
Imminent liquidity and insolvency
Based on reported figures, JAGX trades at a P/S multiple of 0.02, a valuation level that suggests the market is pricing in a high probability of insolvency rather than the potential commercial upside of the company's botanical drug pipeline or its ongoing phase 3 clinical trials.
The extremely low P/S ratio indicates that investors are heavily discounting the company's revenue base due to the persistent cash burn and the lack of a clear path to profitability. This valuation appears to reflect a 'going concern' discount, where the market is prioritizing the immediate risk of dilution or bankruptcy over the long-term value of the intellectual property.
As reported in financial statements, JAGX's ROIC has remained consistently negative over the last ten quarters, with the most recent figures showing a -54.1% return, highlighting the company's inability to generate value from its invested capital while maintaining high R&D and corporate overhead costs.
The persistent negative ROIC suggests that the capital deployed into clinical development and commercialization efforts has not yet yielded a return that exceeds the cost of capital. This trend warrants further investigation into whether the company's current business model can ever achieve the scale necessary to turn these returns positive.
According to quarterly data, the company's cash conversion cycle has been highly volatile, frequently exceeding 800 days, which indicates significant inefficiencies in managing inventory and payables relative to the slow pace of revenue generation from its core Mytesi product in the specialty pharmaceutical market.
The extended CCC suggests that the company is struggling to convert its inventory into cash, likely due to the specialized nature of its botanical supply chain and the challenges of distributing to niche medical markets. This inefficiency exacerbates the company's liquidity constraints, as capital remains tied up in working capital rather than supporting core operations.
Based on the provided data, the EV/EBITDA ratio is frequently misapplied to JAGX, as it obscures the company's fundamental lack of operational scale and the reality that its primary value driver is clinical trial success rather than current earnings or cash flow generation.
Using EBITDA to value a company with deeply negative operating margins and high R&D intensity is fundamentally flawed, as it ignores the massive, necessary cash outflows required for survival. Investors should instead focus on 'cash runway' and the probability-weighted value of the pipeline, as EBITDA metrics provide no insight into the company's ability to reach a self-sustaining commercial state.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying JAGX stock.
Jaguar Health, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Based on historical data, Jaguar Health, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Jaguar Health, Inc. has 67.2% gross margin and -398.8% operating margin.